Jaguar Health, Inc. announced 28-day preclinical toxicology and safety study in dogs Auto News

 

 

SAN FRANCISCO: Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support the development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals ("Napo"), Jaguar's wholly-owned subsidiary, for the symptomatic relief of diarrhea from cholera.

As previously announced, Napo is receiving preclinical services from the National Institute of Allergy and Infectious Diseases ("NIAID") to support lechlemer development. Under NIAID's suite of preclinical services, NIAID-funded contractors are conducting the 28-day dog study. NIAID is part of the National Institutes of Health.

"We are grateful for NIAID's support to conduct this important 28-day toxicity and safety study in dogs, which is expected to support the Investigational New Drug (IND) application we plan to file for lechlemer," stated Steven King, PhD, Jaguar's chief of sustainable supply, ethnobotanical research and IP. "As previously announced, a 28-day preclinical toxicology study in rats to support lechlemer development for the symptomatic relief of diarrhea from cholera was initiated in July of last year. Under NIAID's suite of preclinical services, NIAID-funded contractors also conducted the initial 7-day dog and rat toxicology studies, and completion of these shorter studies allowed for initiation of the longer-term, 28-day, IND-enabling toxicity studies."

The Company believes that lechlemer, which has the same mechanism of action as crofelemer and is significantly less costly to produce, may support development efforts to receive a priority review voucher from the FDA for an indication for the symptomatic relief of diarrhea from cholera. Priority review vouchers are granted by the FDA as an incentive to develop treatments for neglected diseases and rare pediatric diseases. Priority review vouchers are transferable and, in past transactions by other companies, have sold for prices ranging from $67 million to $350 million. Additionally, the Company believes lechlemer represents a long-term pipeline opportunity as a second-generation anti-secretory agent, on a global basis, for multiple gastrointestinal diseases - especially in resource-constrained countries, in part, because requirements often exist in such regions for drug prices to decrease annually.

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae. According to the Centers for Disease Control and Prevention of the U.S. Department of Health & Human Services, an estimated 3?5 million cholera cases and more than 100,000 cholera-related deaths occur each year around the world. The infection is often mild or without symptoms but can sometimes be severe. Approximately one in 10 of infected persons will have severe disease characterized by profuse watery diarrhea, vomiting, and leg cramps. In these people, rapid loss of body fluids leads to dehydration and shock. Without treatment, death can occur within hours. The largest cholera outbreak in recorded history recently occurred in Yemen. According to Oxfam, the number of cholera cases in Yemen in 2019 was the second largest ever recorded in a country in a single year, surpassed only by the numbers in Yemen in 2017. According to the Brookings Institution, cholera continues to spread in Yemen, with 180,000 new cases reported in the first eight months of 2020.

Lechlemer is a drug candidate under the botanical guidance of the U.S. Food and Drug Administration ("FDA"). It is a standardized and proprietary Napo botanical extract that is distinct from Mytesi® (crofelemer), the Company's FDA-approved drug product. Lechlemer is sustainably derived from the same source as Mytesi: the Croton lechleri tree.

The Company has previously presented Phase 2 data on crofelemer for the treatment of devastating dehydration in cholera patients from the renowned International Centre for Diarrhoeal Disease Research (icddr,b) in Bangladesh. Napo plans to follow the same study design for lechlemer.

About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.



Posted Date :  06-01-21

Categories : Auto News

Tag Cloud: Auto News

Similar news

Successful launch of Maruti Suzuki Subscribe

New Delhi: After the successful launch of Maruti Suzuki Subscribe in major cities like Delhi-NCR, Bengaluru, Hyderabad, Pune, Mumbai, Chennai, and Ahmedabad, the Company has added additional models like S-Cross, Ignis and WagonR under the existing Maruti Suzuki Subscribe offering. Subscription ha
Posted Date :  06-01-21

Read more

Skoda christened its midsized SUV-ŠKODA KUSHAQ

Mumbai: ŠKODA AUTO India has christened its midsized SUV, the first vehicle designed and developed under the purview of the 'INDIA 2.0' project, as the 'ŠKODA KUSHAQ'. The naming nomenclature derives its origin from an ancient language of the INDIAN subcontinent, Sanskr
Posted Date :  07-01-21

Read more

Tech Mahindra Ltd collaborates with CME

New Delhi: Makers Lab, the research and development arm of Tech Mahindra Ltd., a leading provider of digital transformation, consulting, and business reengineering services and solutions today announced a collaboration with the College of Military Engineering (CME), Pune to address challenges in the
Posted Date :  05-01-21

Read more

Ford initiated and encourage people on New Year 2021

DEARBORN: As Americans welcome 2021, Ford is kicking off a new initiative to encourage people to come together, protect each other and help save lives in the months ahead until COVID-19 vaccines become more widely distributed. “We’re in this together and Ford’s goal since the pa
Posted Date :  02-01-21

Read more

Ford and Mahindra end discussion for joint venture

DEARBORN: Ford Motor Company and Mahindra & Mahindra have mutually and amicably determined they will not complete a previously announced automotive joint venture between their respective companies.  The decision follows the passing of the Dec. 31 “longstop,” or expiration, date
Posted Date :  02-01-21

Read more

Mahindra published 'Mahindra Good Business Study'

Mumbai: The Mahindra Group today published the findings of the ‘Mahindra Good Business Study’, outlining revealing people’s changing definition of what a ‘Good Business’ actually means. The study, involving over 2,000 respondents across ten, Tier 1 and Tier 2 cities, ai
Posted Date :  01-12-20

Read more

BMW works driver Timo Glock’s Discovery

Munich: As part of a video series, BMW works driver Timo Glock (GER) takes his viewers on a discovery tour through numerous exciting areas of activity and projects within the BMW Group. ‘Timo’s Discovery’ offers exclusive looks behind the scenes. In episode 3, Glock takes on a chal
Posted Date :  01-12-20

Read more

Volkswagen expanding infrastructure- planned 750 new charging points

The Volkswagen brand is significantly expanding the charging infrastructure at its German sites. Some 750 new charging points are planned for next year, including the first High Power Charging stations with up to 300 kW power. Some 2,000 charging points in total are expected to be in operation by th
Posted Date :  30-12-20

Read more

Hyundai wins GOOD DESIGN Award

SEOUL: Hyundai Motor Company announced its win of four accolades at this year’s GOOD DESIGN Awards. Hyundai’s two most progressive EV concepts, 45 and Prophecy, together with the all-new 2021 Hyundai Elantra and the Hyundai Hi-Charger, an ultra-fast EV charging infrastructure, were recog
Posted Date :  30-12-20

Read more

Nissan licensing low-cost technology

YOKOHAMA, Japan: Nissan is supporting the fight against COVID-19 by providing licenses free of charge for thermal imaging sensor technology developed by the company.   Nissan is licensing the low-cost technology under the terms of the IP Open Access Declaration Against COVID-19, whic
Posted Date :  24-12-20

Read more

Nissan launched Note e-POWER AWD compact car

YOKOHAMA, Japan: Nissan today launched the all-new Note e-POWER AWD compact car, with dual electric motors that give the driver enhanced control and acceleration.   The car comes exclusively with Nissan’s e-POWER electrified powertrain and is scheduled to go on sale in Japan in
Posted Date :  24-12-20

Read more

Season 2021: SKODA FABIA Rally2 evo ahead of the 2021

Mladá Boleslav: ŠKODA Motorsport updates the championship winning ŠKODA FABIA Rally2 evo ahead of the 2021 season. Technical improvements throughout the car aim to secure its competitiveness on rally tracks around the world. The new components will be available to customers f
Posted Date :  24-12-20

Read more

Carismatic SUV Nissan Magnite on fire 15000 orders in 15 days

New Delhi: Nissan is going on fire after Nissan India has announced the launch of the price and commenced bookings of the all-new Nissan Magnite across all Nissan dealerships in the country. The big, bold, beautiful, and ‘carismatic’ SUV is available at a special introductory price of
Posted Date :  22-12-20

Read more

MG and IIMPACT inaugurates 15th digital learning center in Mewat

  Mewat, Haryana: MG & IIMPACT today inaugurated their 15th digital learning center in Mewat, Haryana. Taking further their partnership to ensure a better tomorrow for underprivileged girl children, the inauguration was a part of the ‘Digital Centres – E-Shiksha Ek Nayi D
Posted Date :  19-12-20

Read more

MG Motor India joined hands with TES-AMM

New Delhi: Building a robust EV infrastructure to facilitate India’s transition to green mobility, MG Motor India has now joined hands with TES-AMM, a global e-waste recycling and end-to-end service provider. The partnership will ensure environmentally-sustainable and secure recycling of MG
Posted Date :  19-12-20

Read more

Hyundai Motor Group Announces Key Executive Appointments

SEOUL: Hyundai Motor Group announced executive appointments in response to the rapid changes in the business environment and to lead future mobility ecosystem development.    The appointments, which focus on capabilities and expertise, aim to strengthen the Group’s future
Posted Date :  19-12-20

Read more